Test of masitinib versus placebo for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This Phase 3 study tests whether masitinib works better than an inactive pill (placebo) to slow ALS progression and keep it safe. It is meant for people recently diagnosed with ALS who meet specific breathing and function score requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed ALS diagnosis (probable, clinically probable, or definite).
- Your ALS started less than 24 months ago.
- You have been taking riluzole at a stable dose (100 mg/day) for at least 12 weeks before the study starts.
- Your ALS function scores must show clear recent worsening during a short “run-in” period, not just stable symptoms.
- You must have breathing capacity (FVC) of 60% or higher of what is expected for your age, height, and sex.
- You should not have dementia, uncontrolled major health problems, or other conditions that could interfere with the study; and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This study tests a new medicine called BIIB147 to see if it is safe and to learn how it affects people with ALS. It may help slow the progression of the disease.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
This study tests whether the drug colchicine can help people with ALS. It aims to see if taking colchicine in addition to your usual riluzole treatment slows the progression of the disease.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.